Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:57:09.410Z.
Consensus retrieved: 2026-10-06T12:27:12.210Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:57:09.410Z.
Quote observation: 2026-10-06T18:55:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7de6214b49539a8b367d6f361c7a4ef799fc80225bf39e2c2ad4211b42324921
Forward PE Ratio (N/A) = Dated Quote Price ($30.45) / Consensus Forward EPS ($-0.08)
FORWARD PE RATIO
N/A
Harrow Health, Inc.
Market Cap
$1.14B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Harrow Health, Inc. (HROW) | $1.14B | N/A |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 8.68 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.14B | N/A |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A |
| Nektar Therapeutics (NKTR)vs › | $1.14B | N/A |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | N/A |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.11B | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.11B | N/A |
| STAAR Surgical Company (STAA)vs › | $1.10B | 76.41 |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $30.45, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.08 | $-0.13 – $-0.02 | 5 | n/m |
| 2027-12-31 | $2.20 | $0.89 – $3.13 | 6 | 13.9x |
| 2028-12-31 | $3.94 | $2.72 – $5.27 | 4 | 7.7x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
